Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943027 | 0.88 | HSD11B1 (0.38) | HSD11B1ASGR1CHRM2CHRM1CHRM3 | |
| SCHEMBL21997430 | 0.87 | HSD11B1 (0.38) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL31020426 | 0.86 | ASGR1 (0.39) | HSD11B1ASGR1CHRM2CHRM1CHRM3 | |
| SCHEMBL22848661 | 0.84 | HSD11B1 (0.40) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL22836004 | 0.84 | HSD11B1 (0.34) | HSD11B1ASGR1 | |
| SCHEMBL22835655 | 0.83 | HSD11B1 (0.36) | HSD11B1ASGR1DDB1CRBN | |
| SCHEMBL22848660 | 0.83 | HSD11B1 (0.36) | HSD11B1ASGR1DDB1CRBN | |
| SCHEMBL22835947 | 0.83 | HSD11B1 (0.36) | HSD11B1ASGR1DDB1CRBN | |
| SCHEMBL22849436 | 0.83 | HSD11B1 (0.36) | HSD11B1ASGR1DDB1CRBN | |
| SCHEMBL25327534 | 0.82 | HSD11B1 (0.42) | HSD11B1ASGR1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4653442-A1 | POLYCYCLIC COMPOUND FOR TREATING NEUROLOGICAL DISEASES AND TUMORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2024153202-A1 | POLYCYCLIC COMPOUND FOR TREATING NEUROLOGICAL DISEASES AND TUMORS | 中国科学院上海有机化学研究所 | 2024-07-25 | — | — | WO | disclosed |
| CN-118359616-A | Polycyclic compounds as therapeutic agents for neurological diseases and tumors | 中国科学院上海有机化学研究所 | 2024-07-19 | — | — | CN | disclosed |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4076520-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | HSD11B1 2160/4885ASGR1 3426/4885CHRM2 1600/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | HSD11B1 924/4885ASGR1 1556/4885CHRM2 1439/4885 |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885ASGR1 2610/4885CHRM2 4681/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | HSD11B1 1060/4885ASGR1 2099/4885CHRM2 1759/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885ASGR1 2610/4885CHRM2 4681/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885ASGR1 2610/4885CHRM2 4681/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885ASGR1 2610/4885CHRM2 4681/4885 |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885ASGR1 2610/4885CHRM2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.